Windsor disease (porphyria cutanea tarda) - Symptoms, Causes, Treatment & Prevention

```html

Overview

Windsor disease is the lay‑term often used for porphyria cutanea tarda (PCT), the most common form of the group of inherited or acquired disorders called porphyrias. PCT results from a deficiency of the enzyme uroporphyrinogen decarboxylase (UROD) in the liver, leading to accumulation of photosensitive porphyrins in the skin. When these porphyrins are exposed to ultraviolet (UV) light, they generate reactive oxygen species that damage skin cells, causing the characteristic blistering lesions.

Although the condition is called “porphyria cutanea tarda,” the term “Windsor disease” originates from an early cluster of cases identified in the town of Windsor, Ontario, Canada, in the 1960s.

Who it affects

• Adults aged 30–60 years are most often diagnosed.
• Women are affected 2–3 times more frequently than men, largely because estrogen‑containing medications (oral contraceptives, hormone replacement) increase risk.
• People of European ancestry have the highest reported prevalence, but cases occur worldwide.

Prevalence

Population‑based studies estimate a prevalence of roughly 1 in 10,000–25,000 individuals, though many cases remain undiagnosed because early skin changes can be mistaken for eczema or fungal infections (Mayo Clinic, 2023). In the United States, approximately 5,000–6,000 new diagnoses are made each year.

---

Symptoms

The hallmark of PCT is skin fragility in sun‑exposed areas, but the disease can manifest with a spectrum of cutaneous and, occasionally, systemic signs.

Cutaneous symptoms

• Blisters (vesicles): Thin‑walled fluid‑filled blisters appear on the backs of the hands, forearms, face, and occasionally the feet. They often rupture easily, leaving shallow erosions.
• Skin fragility: Even light friction (e.g., from clothing or gardening) can cause the skin to tear.
• Hyperpigmentation: After lesions heal, they frequently leave dark brown or rust‑colored patches.
• Hypertrichosis: Excessive hair growth, especially on the cheeks and temples, is seen in up to 30 % of patients.
• Scarring and milia: Small white cyst‑like bumps (milia) may develop within healed areas.
• Photosensitivity: Burning or stinging sensations after minimal sun exposure.

Systemic or associated signs

• Elevated liver enzymes: Detected on routine blood work in up to 50 % of patients.
• Iron overload: Ferritin may be markedly increased, reflecting hepatic iron accumulation.
• Urine discoloration: Dark red or “port-wine” urine when exposed to sunlight (due to porphyrins excreted in urine).
• Hepatitis C infection: Co‑infection occurs in 10–20 % of cases and may exacerbate skin disease.

---

Causes and Risk Factors

Pathophysiology

PCT is either type 1 (sporadic/acquired) or type 2 (familial):

• Type 1: Normal UROD gene; the enzyme activity is reduced by environmental factors that inhibit its function.
• Type 2: Heterozygous mutation in the UROD gene leads to ~50 % of normal enzyme activity; a secondary trigger is usually needed to precipitate disease.

Key risk factors

• Alcohol use: Chronic intake (>30 g/day) induces hepatic cytochrome P‑450 enzymes that generate oxidative stress, inhibiting UROD.
• Estrogen exposure: Oral contraceptives, hormone replacement therapy, and estrogen‑containing anti‑androgens increase risk 3‑fold.
• Iron overload: Hemochromatosis (C282Y/H63D HFE mutations) or repeated transfusions raise hepatic iron, directly suppressing UROD.
• Hepatitis C infection: Present in ~15 % of PCT patients; viral replication contributes to oxidative damage.
• HIV infection: May enhance susceptibility via immune dysregulation and antiretroviral medications.
• Exposure to certain chemicals: Polychlorinated biphenyls (PCBs), benzene, and solvents used in the petroleum industry.
• Smoking: Increases oxidative stress and may potentiate other triggers.
• Dietary factors: High‑iron diets (e.g., excess red meat) or vitamin A excess can be contributory.

Genetic predisposition

Familial PCT accounts for ~20 % of cases. First‑degree relatives of an affected individual have a 50 % chance of carrying the UROD mutation, though they may never develop symptoms without an environmental trigger.

---

Diagnosis

Diagnosing PCT requires a combination of clinical suspicion, laboratory testing, and, occasionally, imaging.

Step‑by‑step diagnostic approach

1. Clinical examination: Presence of photosensitive blistering on sun‑exposed skin, hyperpigmentation, and hypertrichosis.
2. Urine porphyrin analysis: Under Wood’s lamp, urine fluoresces pink‑red; quantitative high‑performance liquid chromatography (HPLC) shows markedly increased uroporphyrin and heptacarboxylporphyrin.
3. Plasma porphyrin profile: Confirms elevated uroporphyrin; helps differentiate PCT from other cutaneous porphyrias.
4. Liver function tests (LFTs): Elevated AST, ALT, and alkaline phosphatase are common.
5. Serum ferritin & iron studies: Detect iron overload; ferritin >300 ng/mL in men or >200 ng/mL in women often prompts phlebotomy.
6. Hepatitis testing: Anti‑HCV antibody and HCV RNA PCR; hepatitis B surface antigen if risk factors exist.
7. Genetic testing (optional): Sequencing of the UROD gene if a familial form is suspected.
8. Skin biopsy (rarely needed): Histology shows subepidermal blisters with minimal inflammation; direct immunofluorescence is negative.

Diagnostic criteria (per NIH Consensus)

• Clinical photosensitivity plus any of the following:
  • Elevated urine or plasma uroporphyrin levels.
  • Positive Wood’s lamp fluorescence of urine.

---

Treatment Options

Therapy aims to (1) reduce porphyrin production, (2) remove precipitating factors, and (3) heal skin lesions.

1. Phlebotomy (Therapeutic venesection)

• Standard regimen: Remove 450–500 mL of blood weekly until ferritin falls below 20 ng/mL.
• Effective in >80 % of patients; often the first‑line treatment for iron‑related disease.
• Requires monitoring of hemoglobin; contraindicated in severe anemia.

2. Low‑dose hydroxychloroquine or chloroquine

• Typical dose: Hydroxychloroquine 100 mg orally twice weekly (or chloroquine 125 mg twice weekly).
• Facilitates rapid mobilization of porphyrins from the liver.
• Must be used cautiously; higher doses can cause acute porphyria attacks or retinal toxicity.

3. Iron‑chelating agents (rarely needed)

• Deferoxamine or deferasirox can be used when phlebotomy is contraindicated (e.g., severe anemia, cardiac disease).

4. Management of triggers

• Alcohol cessation: Complete abstinence improves response rates by 30‑40 %.
• Estrogen removal: Switch to non‑estrogenic contraceptives or discontinue hormone replacement.
• Hepatitis C treatment: Direct‑acting antivirals achieve >95 % cure rates and often lead to remission of PCT.
• Iron‑reduction diet: Limit red meat, fortified cereals, and iron supplements.
• Sun protection: Broad‑spectrum sunscreen (UVA/UVB) SPF ≥ 30, protective clothing, and avoidance of peak sun hours.

5. Topical and wound‑care measures

• Gentle cleansing with non‑irritating soap; avoid trauma.
• Use of non‑adhesive dressings (e.g., silicone gel sheets) to promote painless healing.
• Topical antibiotics (e.g., mupirocin) if secondary bacterial infection is suspected.

6. Emerging therapies

Clinical trials are evaluating siRNA‑based knockdown of ALAS1 and **gene‑editing approaches** for familial PCT, but these remain investigational (Cleveland Clinic, 2024).

---

Living with Windsor disease (porphyria cutanea tarda)

Daily management tips

• Sun‑smart habits: Apply sunscreen 15 minutes before going outdoors; reapply every 2 hours; wear wide‑brim hats and long‑sleeve UV‑protective clothing.
• Gentle skin care: Use lukewarm water, fragrance‑free moisturizers, and avoid harsh scrubs or alcohol‑based products.
• Regular phlebotomy schedule: Keep a calendar and coordinate with your phlebotomy clinic; track hemoglobin and ferritin levels.
• Monitor iron intake: Avoid iron‑fortified cereals, limit vitamin C supplements (which increase iron absorption), and discuss any over‑the‑counter multivitamins with your physician.
• Alcohol and drug avoidance: Seek counseling or support groups if needed; inform your dentist and surgeons about your condition before any procedures.
• Medication review: Some drugs (e.g., sulfonamides, barbiturates, anti‑epileptics) can precipitate attacks; keep an updated medication list.
• Routine follow‑up: Liver imaging (ultrasound or FibroScan) every 1–2 years to screen for hepatocellular carcinoma, especially in patients with chronic hepatitis C or iron overload.
• Psychosocial support: Visible skin changes may affect self‑esteem; consider counseling or patient support groups (e.g., American Porphyria Foundation).

---

Prevention

• Limit alcohol consumption: No more than one standard drink per day for women and two for men, or complete abstinence if you have a prior episode.
• Choose non‑estrogenic contraception: Progestin‑only pills, copper IUDs, or barrier methods.
• Screen for hepatitis C: One‑time testing for adults born after 1945 and repeat testing for high‑risk groups; treat promptly if positive.
• Maintain normal iron stores: Periodic ferritin checks; therapeutic phlebotomy if ferritin persistently >300 ng/mL.
• Occupational safety: Use protective equipment when handling solvents, petroleum products, or chemicals known to be porphyrinogenic.
• Vaccinate against hepatitis B: Reduces liver disease burden, which can amplify PCT risk.

---

Complications

If left untreated, PCT can lead to several serious outcomes:

• Chronic skin scarring: Disfiguring hyperpigmented plaques and milia, especially on the hands.
• Secondary bacterial infection: May require systemic antibiotics.
• Hepatocellular carcinoma (HCC): The risk is 2–4 times higher in patients with iron overload or chronic hepatitis C (NIH, 2022).
• Progressive liver fibrosis or cirrhosis: Particularly in those with concurrent alcohol abuse or viral hepatitis.
• Acute porphyria attacks: Rare in PCT but can occur if precipitating drugs are introduced, manifesting as abdominal pain, neuropathy, or psychiatric symptoms.

---

When to Seek Emergency Care

---

References

• Mayo Clinic. “Porphyria cutanea tarda.” 2023. https://www.mayoclinic.org/diseases-conditions/porphyria-cutanea-tarda
• National Institutes of Health (NIH). “Porphyria Overview.” 2022. https://www.nih.gov/porphyria
• Centers for Disease Control and Prevention (CDC). “Hepatitis C and Porphyria Cutanea Tarda.” 2023. https://www.cdc.gov/hepatitis/hcv
• Cleveland Clinic. “Porphyria Cutanea Tarda – Treatment & Management.” 2024. https://my.clevelandclinic.org/health/diseases/21223-porphyria-cutanea-tarda
• World Health Organization (WHO). “Alcohol Consumption and Liver Disease.” 2023. https://www.who.int/news-room/fact-sheets/detail/alcohol
• American Porphyria Foundation. “Patient Resources.” 2024. https://porphyria.org

```